We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Universal Health Services (UHS) Hits 52-Week Low on Dull Q3
Read MoreHide Full Article
Shares of Universal Health Services Inc. (UHS - Free Report) tumbled to a 52-week low of $99.56 during the trading session on Nov 8. The slide is believed to have stemmed from poor third-quarter results and a subsequent guidance cut.
Over the past 52 weeks, shares of Universal Health Services have ranged from a low of $99.56 to a high of $129.74. The average volume of shares traded over the last three months is approximately 0.8 million.
Poor Results Bother
Investors were particularly disappointed by lackluster third-quarter earnings which missed the Zacks Consensus Estimate by 3.5%. The top line also missed the estimate by 2%. This was the second miss in a row.
Quite concerning was weak volumes reported by both operating segments — Acute Care and Behavioral Health Hospitals.
In the Acute Care segment, adjusted admission growth slowed to 3.5% in the third quarter compared with growth of 6.5% in the year-ago quarter. Likewise, adjusted patent day witnessed growth of 1.5% versus 3.4% in the third quarter of 2016. Revenue per adjusted admission declined 0.6% compared with growth of 4.4% in last year quarter.
Softness also persisted in the Behavioral Health Hospitals segment with adjusted admission growth declining to 1.1% in the third quarter compared with growth of 1.6% reported in the year-ago quarter. In the same vein, adjusted patent day declined 0.2% versus growth of 1.6% in third-quarter 2016. Revenue per adjusted admission grew just 1.3% compared with growth of 3.3% in the year-ago quarter.
Weakness in volumes from this segment is expected to persist in the coming quarter.
Uninspiring Outlook
Shares also took a toll from its tepid 2017 earnings guidance. Based on the operating trends and financial results experienced during the first nine months of 2017, the company revised its estimated range of adjusted net income attributable for 2017 to $7.25 to $7.50 per diluted share from the previously provided range of $7.50 to $8 per diluted share.
This revised guidance, which excludes the effect of electronic health records impact for the year, as well as the impact of the adoption of ASU 2016-09, decreases the lower end of the previously provided range by approximately 3.3%, and decreases the upper end of the previously provided range by approximately 6.3%.
Price Performance
In a year’s time, the stock has lost 16.7%, significantly underperforming the industry’s decline of 6.5%. Given the headwinds facing the company we do not expect any breather for the stock anytime soon.
Amedisys surpassed earnings estimates in three of the trailing four quarters, resulting in an average positive surprise of 7.2%.
Chemed beat earnings estimates in three of the trailing four quarters, delivering an average positive surprise of 5.9%.
Cigna beat earnings estimates in each of the trailing four quarters, delivering an average positive surprise of 14.6%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Universal Health Services (UHS) Hits 52-Week Low on Dull Q3
Shares of Universal Health Services Inc. (UHS - Free Report) tumbled to a 52-week low of $99.56 during the trading session on Nov 8. The slide is believed to have stemmed from poor third-quarter results and a subsequent guidance cut.
Over the past 52 weeks, shares of Universal Health Services have ranged from a low of $99.56 to a high of $129.74. The average volume of shares traded over the last three months is approximately 0.8 million.
Poor Results Bother
Investors were particularly disappointed by lackluster third-quarter earnings which missed the Zacks Consensus Estimate by 3.5%. The top line also missed the estimate by 2%. This was the second miss in a row.
Quite concerning was weak volumes reported by both operating segments — Acute Care and Behavioral Health Hospitals.
In the Acute Care segment, adjusted admission growth slowed to 3.5% in the third quarter compared with growth of 6.5% in the year-ago quarter. Likewise, adjusted patent day witnessed growth of 1.5% versus 3.4% in the third quarter of 2016. Revenue per adjusted admission declined 0.6% compared with growth of 4.4% in last year quarter.
Softness also persisted in the Behavioral Health Hospitals segment with adjusted admission growth declining to 1.1% in the third quarter compared with growth of 1.6% reported in the year-ago quarter. In the same vein, adjusted patent day declined 0.2% versus growth of 1.6% in third-quarter 2016. Revenue per adjusted admission grew just 1.3% compared with growth of 3.3% in the year-ago quarter.
Weakness in volumes from this segment is expected to persist in the coming quarter.
Uninspiring Outlook
Shares also took a toll from its tepid 2017 earnings guidance. Based on the operating trends and financial results experienced during the first nine months of 2017, the company revised its estimated range of adjusted net income attributable for 2017 to $7.25 to $7.50 per diluted share from the previously provided range of $7.50 to $8 per diluted share.
This revised guidance, which excludes the effect of electronic health records impact for the year, as well as the impact of the adoption of ASU 2016-09, decreases the lower end of the previously provided range by approximately 3.3%, and decreases the upper end of the previously provided range by approximately 6.3%.
Price Performance
In a year’s time, the stock has lost 16.7%, significantly underperforming the industry’s decline of 6.5%. Given the headwinds facing the company we do not expect any breather for the stock anytime soon.
Zacks Rank and Stocks to Consider
Universal Health Services carries a Zacks Rank #5 (Strong Sell). Some of the better-ranked stocks in the health care space are Amedisys Inc. (AMED - Free Report) , Chemed Corp. (CHE - Free Report) and Cigna Corp. (CI - Free Report) . Each of these stocks carries a Zacks Rank # 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Amedisys surpassed earnings estimates in three of the trailing four quarters, resulting in an average positive surprise of 7.2%.
Chemed beat earnings estimates in three of the trailing four quarters, delivering an average positive surprise of 5.9%.
Cigna beat earnings estimates in each of the trailing four quarters, delivering an average positive surprise of 14.6%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>